Results 171 to 180 of about 193,302 (282)

Validation of solvent proteome profiling for antimalarial drug target deconvolution. [PDF]

Int J Parasitol Drugs Drug Resist
Ji Y, Morrow JP, MacRaild CA, Zhang H, Giannangelo C, Schittenhelm RB, Creek DJ, Siddiqui G.   +7 more
europepmc   +1 more source

YIPFα1A expression is regulated by multilayered molecular mechanisms

FEBS Open Bio, EarlyView.
YIPFα1A, a five‐pass Golgi protein, is regulated at multiple layers. (1) Rare‐codon enrichment drives translation‐coupled mRNA decay. (2) A proximal 3′‐UTR element stabilizes mRNA. (3) A distal 3′‐UTR element included by alternate poly(A) site usage represses translation, which can be overridden by the proximal 3′‐UTR element.
Tokio Takaji, Yurika Nakanishi, Nobuhiro Nakamura   +2 more
wiley   +1 more source

Nanostructures as indicator for deformation dynamics. [PDF]

Nat Commun
Incel S, Ohl M, Aben F, Plümper O, Brantut N.   +4 more
europepmc   +1 more source

Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha, Bishwas Mandal, Vishal Mandal, Asis Shrestha, Amir Babu Shrestha   +4 more
wiley   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting. [PDF]

ESC Heart Fail
McCambridge J, Fabamwo F, Taha S, McCaffrey D, Barrett M, Mahon C, McDonald K.   +6 more
europepmc   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

Correction: Sozarukova et al. Gadolinium Doping Modulates the Enzyme-like Activity and Radical-Scavenging Properties of CeO₂ Nanoparticles. <i>Nanomaterials</i> 2024, <i>14,</i> 769. [PDF]

Nanomaterials (Basel)
Sozarukova MM, Kozlova TO, Beshkareva TS, Popov AL, Kolmanovich DD, Vinnik DA, Ivanova OS, Lukashin AV, Baranchikov AE, Ivanov VK.   +9 more
europepmc   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Metal-Assisted Deprotonation as a Key Step in Selective Copper Extraction: A Theoretical and Experimental Study. [PDF]

Int J Mol Sci
Maurelia R, Zamora PP, Galleguillos Madrid FM, Jiménez-Arévalo VM.   +3 more
europepmc   +1 more source

Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke: A Multicenter Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai, Yang Qu, Reziya Abuduxukuer, Kejia Zhang, Peng Zhang, Xin Tang, Huaimei Zhang, Lijuan Wang, Lichong Yang, Shuangxu Tan, Zhimei Yuan, Ce Han, Lili He, Yuping Zheng, Fenglan Zhao, Lijie Guo, Ligang Jiang, Jinfeng Li, Yongfei Jiang, Xuexia Zou, Dan Xu, Han Xu, Xiaojia Wang, Yingbin Qi, Xuefeng Hu, Yu Zhang, Zhen‐Ni Guo, Hang Jin, on behalf of the Biomarkers of Brain Injury Investigator Study Group   +28 more
wiley   +1 more source